Severity
Moderate
FDA Drug recall · Reported August 24, 2022
Failed Impurities/Degradation Specifications
Zydus Pharmaceuticals (USA) Inc recalled Fulvestrant Injection 250mg/5mL (50 mg/mL), Contains 2 Single-Dose Prefilled Syringes, Rx… - a moderate-severity action.
Fulvestrant Injection 250mg/5mL (50 mg/mL), Contains 2 Single-Dose Prefilled Syringes, Rx… was recalled by Zydus Pharmaceuticals (USA) Inc in August 24, 2022. Reason: Failed Impurities/Degradation Specifications. Check the official notice for the remedy. Verify recall #D-1351-2022 with the FDA Drug before acting.
The recall
Zydus Pharmaceuticals (USA) Inc issued this moderate-severity FDA Drug recall-Failed Impurities/Degradation Specifications.
Sourced from official FDA Drug enforcement records. Verify recall #D-1351-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1351-2022) was formally reported on August 24, 2022, with the manufacturer initiating the action on July 15, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Zydus Pharmaceuticals (USA) Inc is listed as the recalling firm, operating out of Pennington, NJ. Federal records list the affected scope as 1116 boxes.
The documented reason for this recall is: Failed Impurities/Degradation Specifications Distribution data in the federal record shows the product reached: Nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
1116 boxes
Related Recalls
6
5 from same agency
Fulvestrant Injection 250mg/5mL (50 mg/mL), Contains 2 Single-Dose Prefilled Syringes, Rx Only, Product of India, Manufactured by: Cadila Healthcare Limited, Ahmadabad, India, Distributed by: Zydus Pharmaceuticals (USA ) Inc.m Pennington, NJ 08534, NDC 70710-1688-8.
Failed Impurities/Degradation Specifications
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1351-2022 |
| Date reported | August 24, 2022 |
| Date initiated | July 15, 2022 |
| Recalling firm | Zydus Pharmaceuticals (USA) Inc |
| Firm location | Pennington, NJ |
| Affected scope | 1116 boxes |
| Distribution | Nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported August 24, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.